NEW YORK – CareDx said on Friday that it has received the CE mark for its AlloSeq cfDNA kit, making it available to transplant patients and clinicians in Europe.
AlloSeq cfDNA is a kit-based product that is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health, and is run on next generation sequencing platforms.